
Nasser H Zawia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10812604/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Alzheimer's Disease (AD)-Like Pathology in Aged Monkeys after Infantile Exposure to Environmental Metal Lead (Pb): Evidence for a Developmental Origin and Environmental Link for AD. Journal of Neuroscience, 2008, 28, 3-9.	1.7	438
2	The Fetal Basis of Amyloidogenesis: Exposure to Lead and Latent Overexpression of Amyloid Precursor Protein and Â-Amyloid in the Aging Brain. Journal of Neuroscience, 2005, 25, 823-829.	1.7	338
3	Epigenetics, oxidative stress, and Alzheimer disease. Free Radical Biology and Medicine, 2009, 46, 1241-1249.	1.3	311
4	Exposure to lead (Pb) and the developmental origin of oxidative DNA damage in the aging brain. FASEB Journal, 2006, 20, 788-790.	0.2	156
5	How and When Environmental Agents and Dietary Factors Affect the Course of Alzheimers Disease: The "LEARn" Model (Latent Early-Life Associated Regulation) May Explain the Triggering of AD. Current Alzheimer Research, 2007, 4, 219-228.	0.7	140
6	Infant Exposure to Lead (Pb) and Epigenetic Modifications in the Aging Primate Brain: Implications for Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 27, 819-833.	1.2	140
7	Epigenetics: A novel therapeutic approach for the treatment of Alzheimer's disease. , 2013, 139, 41-50.		95
8	Environmental and dietary risk factors in Alzheimer's disease. Expert Review of Neurotherapeutics, 2007, 7, 887-900.	1.4	93
9	The Environment, Epigenetics and Amyloidogenesis. Journal of Molecular Neuroscience, 2008, 34, 1-7.	1.1	90
10	Enhanced taupathy and AD-like pathology in aged primate brains decades after infantile exposure to lead (Pb). NeuroToxicology, 2013, 39, 95-101.	1.4	89
11	Lead (Pb) exposure and its effect on APP proteolysis and AÎ ² aggregation. FASEB Journal, 2005, 19, 2083-2084.	0.2	87
12	Genome-wide expression and methylation profiling in the aged rodent brain due to early-life Pb exposure and its relevance to aging. Mechanisms of Ageing and Development, 2012, 133, 435-443.	2.2	80
13	Infantile exposure to lead and lateâ€age cognitive decline: Relevance to AD. Alzheimer's and Dementia, 2014, 10, 187-195.	0.4	79
14	Environmental Risk Factors and the Developmental Basis for Alzheimer's Disease. Reviews in the Neurosciences, 2005, 16, 325-37.	1.4	66
15	Infantile postnatal exposure to lead (Pb) enhances tau expression in the cerebral cortex of aged mice: Relevance to AD. NeuroToxicology, 2014, 44, 114-120.	1.4	65
16	Developmental lead exposure and lifespan alterations inÂepigeneticÂregulators and their correspondence to biomarkers ofÂAlzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 123-131.	1.2	65
17	Pomegranate ellagitannin-gut microbial-derived metabolites, urolithins, inhibit neuroinflammation <i>in vitro</i> . Nutritional Neuroscience, 2019, 22, 185-195.	1.5	65
18	Early-Life Exposure to Lead (Pb) Alters the Expression of microRNA that Target Proteins Associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 51, 1257-1264.	1.2	60

NASSER H ZAWIA

#	Article	IF	CITATIONS
19	Early-life events may trigger biochemical pathways for Alzheimer's disease: the "LEARn―model. Biogerontology, 2008, 9, 375-379.	2.0	58
20	In vitro Pb exposure disturbs the balance between Aβ production and elimination: The role of AβPP and neprilysin. NeuroToxicology, 2011, 32, 300-306.	1.4	54
21	Alzheimer's Disease Biomarkers and Epigenetic Intermediates Following Exposure to Pb In Vitro. Current Alzheimer Research, 2012, 9, 555-562.	0.7	54
22	Do Epigenetic Pathways Initiate Late Onset Alzheimer Disease (LOAD): Towards a New Paradigm. Current Alzheimer Research, 2012, 9, 574-588.	0.7	46
23	c-fos and ornithine decarboxylase gene expression in brain as early markers of neurotoxicity. Brain Research, 1991, 544, 291-296.	1.1	44
24	Utilization of a Synthetic Peptide as a Tool to Study the Interaction of Heavy Metals with the Zinc Finger Domain of Proteins Critical for Gene Expression in the Developing Brain. Toxicology and Applied Pharmacology, 2000, 166, 1-12.	1.3	43
25	Short-term treatment with tolfenamic acid improves cognitive functions in Alzheimer's disease mice. Neurobiology of Aging, 2013, 34, 2421-2430.	1.5	40
26	Tolfenamic acid downregulates BACE1 and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. Neuropharmacology, 2014, 79, 596-602.	2.0	34
27	Ontogenetic alterations in prototypical transcription factors in the rat cerebellum and hippocampus following perinatal exposure to a commercial PCB mixture. NeuroToxicology, 2006, 27, 118-124.	1.4	28
28	Lifespan Profiles of Alzheimer's Disease-Associated Genes and Products in Monkeys and Mice. Journal of Alzheimer's Disease, 2009, 18, 211-230.	1.2	28
29	Integration of genome-wide expression and methylation data: Relevance to aging and Alzheimer's disease. NeuroToxicology, 2012, 33, 1450-1453.	1.4	26
30	Co-localization and Distribution of Cerebral APP and SP1 and its Relationship to Amyloidogenesis. Journal of Alzheimer's Disease, 2008, 13, 71-80.	1.2	25
31	The Ability of Tolfenamic Acid to Penetrate the Brain: A Model for Testing the Brain Disposition of Candidate Alzheimers Drugs Using Multiple Platforms. Current Alzheimer Research, 2011, 8, 860-867.	0.7	24
32	Latent consequences of early-life lead (Pb) exposure and the future: Addressing the Pb crisis. NeuroToxicology, 2018, 68, 126-132.	1.4	24
33	Tolfenamic acid reduces tau and <scp>CDK</scp> 5 levels: implications for dementia and tauopathies. Journal of Neurochemistry, 2015, 133, 266-272.	2.1	23
34	Transcriptional involvement in neurotoxicity. Toxicology and Applied Pharmacology, 2003, 190, 177-188.	1.3	22
35	Cellular and Organismal Toxicity of the Anti-Cancer Small Molecule, Tolfenamic Acid: a Pre-Clinical Evaluation. Cellular Physiology and Biochemistry, 2013, 32, 675-686.	1.1	21
36	Influence of Early Life Lead (Pb) Exposure on α-Synuclein, GSK-3β and Caspase-3 Mediated Tauopathy: Implications on Alzheimer's Disease. Current Alzheimer Research, 2018, 15, 1114-1122.	0.7	19

NASSER H ZAWIA

#	Article	IF	CITATIONS
37	Intranigral iron infusion in the rat. Biological Trace Element Research, 1997, 58, 177-195.	1.9	18
38	Reduction of Amyloid-β Deposition and Attenuation of Memory Deficits by Tolfenamic Acid. Journal of Alzheimer's Disease, 2014, 43, 425-433.	1.2	16
39	Lead exposure and tau hyperphosphorylation: An in vitro study. NeuroToxicology, 2017, 62, 218-223.	1.4	16
40	Histone acetylation maps in aged mice developmentally exposed to lead: epigenetic drift and Alzheimer-related genes. Epigenomics, 2018, 10, 573-583.	1.0	15
41	Characterization of nigerlysin $\hat{A} @$, hemolysin produced by Aspergillus niger, and effect on mouse neuronal cells in vitro. Toxicology, 2006, 219, 150-155.	2.0	14
42	Fenamates as Potential Therapeutics for Neurodegenerative Disorders. Cells, 2021, 10, 702.	1.8	14
43	Developmental Perfluorooctanesulfonic acid (PFOS) exposure as a potential risk factor for late-onset Alzheimer's disease in CD-1 mice and SH-SY5Y cells. NeuroToxicology, 2021, 86, 26-36.	1.4	14
44	Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy. Current Alzheimer Research, 2018, 15, 655-663.	0.7	14
45	Altered microRNA, mRNA, and Protein Expression of Neurodegeneration-Related Biomarkers and Their Transcriptional and Epigenetic Modifiers in a Human Tau Transgenic Mouse Model in Response to Developmental Lead Exposure. Journal of Alzheimer's Disease, 2018, 63, 273-282.	1.2	12
46	An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients. Schizophrenia Research, 2008, 100, 86-96.	1.1	11
47	Lead Exposure: Expression and Activity Levels of Oct-2 in the Developing Rat Brain. Toxicological Sciences, 2006, 95, 436-442.	1.4	10
48	Unique aspects of the epigenetic code in the brain. Epigenomics, 2017, 9, 1157-1159.	1.0	2
49	How Biochemical Pathways for Disease May be Triggered by Early-Life Events. , 2009, , 205-214.		1
50	An Epigenetic Model for Susceptibility to Oxidative DNA Damage in the Aging Brain and Alzheimer's Disease. , 2010, , 439-453.		1
51	Epigenetics and Late-Onset Alzheimer's Disease. , 2011, , 175-186.		1